Literature DB >> 11467695

Human chorionic gonadotrophin inhibition of pregnant human myometrial contractility.

M M Slattery1, C Brennan, M J O'Leary, J J Morrison.   

Abstract

OBJECTIVE: To evaluate the effect of human chorionic gonadotrophin (hCG) on pregnant human myometrial contractility in vitro and to determine whether the hCG-elicited effect was oestrogen dependant.
METHODS: Isometric tension recording was performed under physiological conditions in isolated myometrial strips from biopsies obtained at elective caesarean section. The effect of cumulative additions of hCG (0.001, 0.01, 0.1, 1.0 and 10 iu/mL) on myometrial contractility was evaluated. Secondarily, the contractile activity of pregnant myometrium following hCG exposure was investigated in tissue pre-treated with beta-oestradiol.
RESULTS: hCG exerted a statistically significant relaxant effect on pregnant human myometrial tissue. The relaxant effect increased with increasing concentrations of hCG from 8.96% (SEM 2.06) (0.001 iu/mL hCG: P < 0.01 ) to a net cumulative total of 58.50% (SEM 3.74) (10 iu/mL hCG; P < 0.01). The relaxant effect was also time-dependant, increasing in magnitude throughout the duration of experiments. Beta-oestradiol did not significantly affect the response of myometrial tissue to hCG.
CONCLUSIONS: These results clearly demonstrate that hCG exerts a significant concentration-dependant relaxant effect on human myometrial tissue obtained rate in pregnancy. These findings outline an inhibitory physiological role of hCG on human myometrial contractility and raise the possibility of its potential use as a tocolytic.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11467695     DOI: 10.1111/j.1471-0528.2001.00178.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  7 in total

1.  Distribution and quantitative changes in amounts of aquaporin 1, 5 and 9 in the pig uterus during the estrous cycle and early pregnancy.

Authors:  Mariusz T Skowronski
Journal:  Reprod Biol Endocrinol       Date:  2010-09-09       Impact factor: 5.211

2.  Human Chorionic Gonadotropin Modulates the Transcriptome of the Myometrium and Cervix in Late Gestation.

Authors:  Kenichiro Motomura; Roberto Romero; Jose Galaz; Derek Miller; Bogdan Done; Marcia Arenas-Hernandez; Valeria Garcia-Flores; Li Tao; Adi L Tarca; Nardhy Gomez-Lopez
Journal:  Reprod Sci       Date:  2021-03-01       Impact factor: 2.924

Review 3.  Modulators of the Balance between M1 and M2 Macrophages during Pregnancy.

Authors:  Yong-Hong Zhang; Ming He; Yan Wang; Ai-Hua Liao
Journal:  Front Immunol       Date:  2017-02-09       Impact factor: 7.561

4.  Intramuscular injection of human chorionic gonadotropin prior to secretory transformation in patients undergoing frozen-thawed embryo transfer cycles.

Authors:  Ling Deng; Xin Chen; Christophe Blockeel; De-Sheng Ye; Shi-Ling Chen
Journal:  Reprod Biol Endocrinol       Date:  2020-05-25       Impact factor: 5.211

Review 5.  Overview. Preterm labour: mechanisms and management.

Authors:  Andrés López Bernal
Journal:  BMC Pregnancy Childbirth       Date:  2007-06-01       Impact factor: 3.007

6.  Human Chorionic Gonadotropin Has Anti-Inflammatory Effects at the Maternal-Fetal Interface and Prevents Endotoxin-Induced Preterm Birth, but Causes Dystocia and Fetal Compromise in Mice.

Authors:  Amy-Eunice Furcron; Roberto Romero; Tara N Mial; Amapola Balancio; Bogdan Panaitescu; Sonia S Hassan; Aashna Sahi; Claire Nord; Nardhy Gomez-Lopez
Journal:  Biol Reprod       Date:  2016-05-04       Impact factor: 4.285

7.  Insights into the hyperglycosylation of human chorionic gonadotropin revealed by glycomics analysis.

Authors:  Linda Ibeto; Aristotelis Antonopoulos; Paola Grassi; Poh-Choo Pang; Maria Panico; Shabnam Bobdiwala; Maya Al-Memar; Paul Davis; Mark Davis; Julian Norman Taylor; Paula Almeida; Mark R Johnson; Richard Harvey; Tom Bourne; Michael Seckl; Gary Clark; Stuart M Haslam; Anne Dell
Journal:  PLoS One       Date:  2020-02-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.